Emerson Electric
EMR
$144.56
+0.07%
Emerson Electric Co. is a leading industrial automation company that designs and manufactures a wide range of automation software, hardware, and power tools, operating within the Industrial - Machinery sector. The company has established itself as a market leader through strategic acquisitions and a recent transformation into a pure-play automation provider, having divested its climate technology and consumer businesses. The current investor narrative centers on the company's strategic pivot and its positioning to capitalize on the long-term secular trend of factory automation, which promises to enhance productivity and safety for manufacturers, a focus evident in its recent financial results and strategic communications.…
EMR
Emerson Electric
$144.56
Investment Opinion: Should I buy EMR Today?
Rating & Thesis: Hold. Emerson is a high-quality company in a favorable long-term trend, but its current premium valuation fully reflects this optimism, creating an unfavorable risk/reward profile for new capital. This aligns with the neutral-to-cautious analyst consensus evidenced by the recent downgrade.
Supporting Evidence: The stock trades at a forward PE of 20.11x, which, while a discount to its trailing multiple, still represents a premium valuation. Revenue growth has decelerated to 4.07% YoY in the latest quarter. However, this is offset by strong profitability, with a net margin of 12.73% and robust TTM FCF of $2.575 billion. The implied upside to analyst targets is unclear from the provided EPS estimates alone, but the stock's retreat from its highs suggests it is trading closer to fair value.
Risks & Conditions: The two biggest risks are valuation compression and a further slowdown in industrial automation spending. This Hold rating would upgrade to a Buy if the forward PE compresses below 17x (offering a margin of safety) or if quarterly revenue growth re-accelerates sustainably above 8% YoY. It would downgrade to a Sell if revenue turns negative or the operating margin falls below 15%. Relative to its history and growth trajectory, the stock is currently fairly valued to slightly overvalued.
Sign up to view all
EMR 12-Month Price Forecast
The outlook for Emerson is one of high-quality execution within a challenging valuation context. The company's strategic positioning and financial health are undeniable strengths, but the market has largely rewarded this story, baking optimistic growth into the price. The most likely path (Base Case) is one of consolidation as the company works to prove it can grow into its valuation. The stance is neutral because the risk of multiple compression in a slowdown roughly balances the opportunity for growth re-acceleration. We would upgrade to bullish on evidence of sustained revenue re-acceleration (>6% for two consecutive quarters) or a material pullback to a forward PE near 17x. A downgrade to bearish would follow a confirmed break below the $123 technical support level on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $187.93 and implied upside of +30.0% versus the current price.
Average Target
$187.93
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$116 - $188
Analyst target range
Analyst coverage for Emerson is moderate with 7 analysts providing estimates, indicating steady institutional interest. The consensus sentiment leans neutral to cautiously optimistic, with recent actions including a mix of reiterations and a notable downgrade from Deutsche Bank from 'Buy' to 'Hold' in early February 2026. The target price range, implied by estimated EPS, spans from a low of $8.93 to a high of $9.36; a wide spread between the high and low EPS estimates signals some uncertainty or divergence in views on the company's near-term earnings power, which can contribute to stock price volatility.
Bulls vs Bears: EMR Investment Factors
The evidence presents a balanced but tense picture. The bull case is anchored in Emerson's successful strategic pivot to a high-growth automation theme, robust profitability, and a strong balance sheet. The bear case focuses on decelerating revenue, a full valuation, and emerging signs of analyst skepticism. Currently, the bull side holds a slight edge due to the powerful secular tailwind and strong execution metrics, but the valuation premium is the single most important tension. The investment debate hinges on whether Emerson's earnings growth can accelerate sufficiently to justify and sustain its elevated PE multiple, or if a period of multiple compression is inevitable.
Bullish
- Strong Strategic Pivot to Pure-Play Automation: The company's transformation into a pure-play industrial automation provider positions it to capitalize on a powerful secular trend. This strategic focus is validated by a 44.16% stock price increase over the past year, significantly outperforming the S&P 500's 29.52% gain.
- Robust Profitability and Cash Flow Generation: Emerson maintains strong profitability with a Q1 2026 operating margin of 19.80% and a net margin of 12.73%. The company generates substantial free cash flow, with $2.575 billion TTM, providing ample capital for reinvestment, dividends, and buybacks.
- Healthy Balance Sheet with Manageable Debt: Financial health is solid, supported by a conservative debt-to-equity ratio of 0.68 and a return on equity of 11.31%. This low leverage provides strategic flexibility and resilience in a higher interest rate environment.
- Forward PE Implies Significant Earnings Growth: The forward PE of 20.11x represents a significant discount to the trailing PE of 32.20x, indicating the market is pricing in strong earnings growth for the coming year. This is supported by analyst consensus EPS estimates averaging $9.17.
Bearish
- Revenue Growth Deceleration and Cyclicality: Recent Q1 2026 revenue of $4.345 billion grew only 4.07% YoY and declined sequentially from Q4 2025's $4.855 billion. This deceleration suggests potential cyclical headwinds or segment-specific pressures in the industrial automation market.
- Premium Valuation at Peak Historical Multiples: The trailing PE of 32.20x is at a significant premium to the sector and is near the upper end of the stock's own historical range (15.69x - 31.97x). This leaves little room for error and makes the stock vulnerable to multiple compression if growth disappoints.
- Recent Downgrade and Analyst Uncertainty: Analyst sentiment shows cracks, with Deutsche Bank downgrading from 'Buy' to 'Hold' in February 2026. Furthermore, the wide spread between high ($9.36) and low ($8.93) EPS estimates signals underlying uncertainty about near-term earnings power.
- High Volatility and Recent Price Retreat: With a beta of 1.28, the stock is 28% more volatile than the market. It has retreated from its 52-week high of $165.15 to $143.77, a 13% decline, and recently tested support near $123.30, indicating heightened sensitivity to market sentiment shifts.
EMR Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 44.16% price increase over the past year. As of the latest close at $143.77, the stock is trading at approximately 69% of its 52-week range ($95.31 to $165.15), indicating it has retreated meaningfully from its highs but remains well above its lows, suggesting a consolidation phase within a broader bull market. Recent momentum shows a divergence, with a strong 3.01% gain over the past month contrasting with a slight 0.30% decline over the past three months; this one-month outperformance, especially against the S&P 500's 0.46% gain, signals a potential resumption of the primary uptrend after a period of correction. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $165.15 and support at the 52-week low of $95.31; a breakout above resistance would confirm renewed bullish momentum, while a sustained break below the recent March low near $123.30 could signal a deeper correction. The stock's beta of 1.28 indicates it is approximately 28% more volatile than the broader market, which investors must account for in risk management and position sizing.
Beta
1.28
1.28x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$95-$165
Price range past year
Annual Return
+43.1%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | +9.3% | +4.9% |
| 3m | -2.4% | +0.6% |
| 6m | +12.2% | +5.1% |
| 1y | +43.1% | +28.8% |
| ytd | +6.4% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Revenue growth is positive but has shown variability, with the most recent Q1 2026 revenue of $4.345 billion representing a 4.07% year-over-year increase; however, this marks a deceleration from the prior quarter's (Q4 2025) revenue of $4.855 billion, indicating potential cyclicality or segment-specific pressures. The company is solidly profitable, reporting net income of $605 million for Q1 2026, with a gross margin of 48.56% and an operating margin of 19.80%; while the gross margin dipped from 51.91% in the prior quarter, the operating margin improved significantly from 13.10%, suggesting effective cost management. Financial health is strong, supported by a manageable debt-to-equity ratio of 0.68, a robust trailing twelve-month free cash flow of $2.575 billion, and a return on equity of 11.31%; this substantial FCF generation provides ample internal funding for growth initiatives, dividends, and share repurchases while maintaining a conservative balance sheet.
Quarterly Revenue
$4.3B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.48%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 32.20x and a forward PE of 20.11x; the significant discount of the forward multiple implies the market anticipates strong earnings growth in the coming year. Compared to sector averages, Emerson's trailing PE of 32.20x is at a significant premium; this premium is likely justified by its leading market position in industrial automation, strategic refocusing, and superior profitability metrics like its net margin of 12.73%. Historically, the current trailing PE of 32.20x is above the stock's own recent historical range, which has fluctuated between approximately 15.69x and 31.97x over the past several quarters; trading near the upper end of this band suggests the market has already priced in optimistic expectations for future execution and growth.
PE
32.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage but valuation dependency on growth. The stock's trailing PE of 32.20x is predicated on sustained high earnings growth. A deceleration in revenue growth, as seen in the sequential decline from Q4 to Q1 2026, could trigger significant earnings misses and a derating. While the balance sheet is strong with a D/E of 0.68, operating margins showed volatility, with the gross margin dipping from 51.91% to 48.56% last quarter, indicating potential cost or pricing pressures.
Market & Competitive Risks: The stock faces pronounced valuation compression risk, trading at a premium to both its sector and its own historical range. Its beta of 1.28 means it is highly sensitive to broader market downturns and sector rotations away from growth-oriented industrials. Competitive risks are inherent as Emerson's pure-play automation strategy puts it in direct competition with other large-cap industrials and specialized tech firms vying for the same factory modernization budgets, potentially pressuring long-term pricing power.
Worst-Case Scenario: The worst-case scenario involves a combination of an industrial recession slowing capital expenditure, a failure to meet the high earnings growth priced into the forward multiple, and a broad market sell-off amplifying the stock's inherent volatility. This could trigger a cascade of analyst downgrades and a re-rating towards its historical PE low. The realistic downside could see the stock retreat to its 52-week low of $95.31, representing a potential loss of approximately -34% from the current price of $143.77, aligning with its historical max drawdown of -23.74%.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: The high PE multiple makes the stock vulnerable to compression if growth disappoints. 2) Cyclical/Execution Risk: Recent revenue deceleration (Q1 growth of 4.07%) suggests sensitivity to industrial cycles; failure to re-accelerate would hurt the thesis. 3) Market Risk: With a beta of 1.28, EMR is likely to fall more than the market in a downturn. 4) Competitive Risk: The focus on automation invites competition from both traditional industrials and software firms, potentially pressuring margins.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $140 and $160 as it consolidates recent gains, assuming steady execution and earnings meeting the $9.17 consensus. The Bull Case (25% probability) targets $165 to $175 on re-accelerating growth and margin expansion. The Bear Case (15% probability) warns of a drop to $95-$125 if an industrial slowdown triggers earnings misses and multiple compression. The Base Case is most likely, hinging on the assumption that current analyst estimates are accurate.
EMR appears fairly valued to slightly overvalued based on current metrics. Its trailing PE of 32.20x is at a premium to the industrial sector and near the top of its own historical range. The forward PE of 20.11x is more reasonable and implies expected earnings growth, but it still leaves little room for error. The valuation implies the market expects Emerson to successfully execute its pure-play automation strategy and deliver mid-to-high single-digit earnings growth consistently. Any stumble could lead to a derating.
EMR is a good stock for investors already convinced of the long-term industrial automation thesis and seeking a financially sound player, but it is not an compelling buy at the current moment for new capital. The stock has had a tremendous 44% run over the past year and now trades at a premium valuation (forward PE of 20.11x) with recent signs of growth deceleration (4.07% YoY in Q1). The ~34% potential downside to its 52-week low presents a significant risk. It is a better buy on a meaningful pullback or after evidence of re-accelerating growth emerges.
EMR is more suitable for a long-term investment horizon of 3-5 years. Its thesis is based on a secular, multi-year trend of factory automation, not short-term catalysts. The stock's higher volatility (beta 1.28) and lack of a high dividend yield (1.61%) make it less ideal for short-term trading or income-focused portfolios. A long-term horizon allows investors to look through potential cyclical downturns and benefit from the strategic transformation. A minimum holding period of 18-24 months is suggested to properly assess the execution of its pure-play strategy.